No immediate trading catalyst. Monitor the next quarterly earnings call for any strategic or capital allocation shifts under the new CFO. The appointment of a seasoned J&J finance executive is incrementally positive for governance credibility but does not change near-term fundamentals.
HALO drugs
HALO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 30 $63.66entry
- T+1 · 7mo ago +0.47%α +0.25% · $63.96
- T+5 · 6mo ago +4.23%α +2.50% · $66.35
- T+20 · 6mo ago +7.10%α +2.13% · $68.18
- T+60 · 4mo ago +27.99%α +24.88% · $81.48
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Halozyme appointed Darren Snellgrove as permanent CFO, effective June 8, 2026, replacing interim CFO David Ramsay who will stay on in an advisory role. Snellgrove brings deep biopharma finance experience from 27 years at Johnson & Johnson, most recently as VP of Investor Relations and previously as CFO of J&J's Pharmaceutical sector. This is a routine executive appointment with no material financial impact.
Key Facts
- Darren Snellgrove appointed CFO effective June 8, 2026, replacing interim CFO David Ramsay
- Snellgrove spent 27 years at Johnson & Johnson, most recently as VP of Investor Relations and previously as CFO of J&J's Pharmaceutical sector
- Annual base salary of $670,000 with 50% bonus target, new-hire equity awards totaling $7,200,000 ($3.2M RSUs + $4.0M stock options), and a $350,000 sign-on cash bonus
- Current interim CFO David Ramsay will remain in an advisory role during the transition
Financial Impact
New CFO compensation package includes $670,000 salary, $7.2M equity grant, and $350,000 sign-on bonus, immaterial relative to $7.5B market cap
Risk Factors
- Transition risk if Snellgrove's strategic priorities diverge from the interim CFO's approach
- No change to underlying business fundamentals or revenue outlook
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001159036-26-000053 |
| Document: darrensnellgrovepressrelea.htm | 0001159036-26-000053 |
| Document: 0001159036-26-000053-index-headers.html | 0001159036-26-000053 |
| Document: 0001159036-26-000053-index.html | 0001159036-26-000053 |
| Document: 0001159036-26-000053.txt | 0001159036-26-000053 |
Track record
15 reports on HALO
1 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +17.70% at T+20 after the Oct 15, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 9, 20268d ago PTAB Trial Bearish 6/10 Entry $102.98 Now $96.50 +6.29% settles Nov 17
- Nov 6, 202610d ago Press Release Bullish 6/10 Entry $103.63 to $100.27 Now $96.50 −6.88% ▼ −3.24% −5.84% vs SPY
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $103.63 to $100.27 Now $96.50 −6.88% ▼ −3.24% −5.84% vs SPY
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $124.54 to $131.18 Now $96.50 −22.51% ▲ +5.33% +4.62% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bullish 4/10 Entry $124.83 to $128.50 Now $96.50 −22.69% ▲ +2.94% +3.38% vs SPY
- Oct 15, 20264w ago PTAB Trial Bearish 7/10 Entry $121.84 to $125.63 Now $96.50 +20.80% ▼ −3.11% −3.54% vs SPY
- Oct 15, 20264w ago PTAB Trial Bearish 7/10 Entry $121.84 to $125.63 Now $96.50 +20.80% ▼ −3.11% −3.54% vs SPY
- Sep 18, 20268w ago 8-K Mixed 6/10 Entry $112.45 to $113.90 Now $96.50 −14.18% ▲ +1.29% +0.02% vs SPY
- Sep 17, 20268w ago Insider Cluster Neutral 2/10 Entry $112.45 to $113.90 Now $96.50 −14.18% ▲ +1.29% +0.02% vs SPY
- Aug 19, 202612w ago Insider Cluster Neutral 2/10 Entry $106.12 to $106.92 Now $96.50 −9.07% ▲ +0.75% −0.36% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers